Long COVIDEAV-LONGCOVIDNCT07343856
Long COVID Diagnostic Reactivity Assesment Test
A study testing Electrodiagnostic Bioelectrical Assessment in people with Long COVID and Post-Acute Sequelae of SARS-CoV-2 Infection, run by Oncology Center,Ministry Of Heath,Uzbekistan at 1 site in Uzbekistan.
Trial summary
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing. The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Long COVID, Post-Acute Sequelae of SARS-CoV-2 Infection
- What is being tested?
- Electrodiagnostic Bioelectrical Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUzbekistan
- Study dates
- 5 Dec 2025to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- History of confirmed SARS-CoV-2 infection
- Persistent symptoms consistent with Long COVID lasting ≥12 weeks after acute infection
- Ability to provide informed consent
- Willingness to undergo non-invasive bioelectrical diagnostic assessment
Who cannot join
- Acute infectious disease at the time of enrollment
- Severe uncontrolled medical or psychiatric conditions that may interfere with diagnostic assessment
- Implanted electronic medical devices (e.g., pacemaker)
- Pregnancy or breastfeeding
- Inability to comply with study procedures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Development of a Personalized Alternative Non-invasive Rapid Diagnostic Test for SARS-CoV-2 in Patients With Long COVID
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without administration of pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
Read the detailed description
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
- Being tested
- Electrodiagnostic Bioelectrical Assessment
- Keywords
- Long COVID, Post-acute sequelae of SARS-CoV-2 infection, Bioelectrical assessment, Electroacupuncture diagnostics, Medicament testing, Autonomic dysregulation, Chronic viral persistence, Non-invasive diagnostics
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Primary Dysautonomias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrodiagnostic Bioelectrical AssessmentDiagnostic test
A non-invasive diagnostic procedure performed during a single session to assess bioelectrical response patterns associated with viral antigen persistence. Measurements are obtained using standardized bioelectrical assessment techniques without administration of any therapeutic agents or interventions.
| Study group | Role | What they receive |
|---|---|---|
| Diagnostic Assesment Arm | Experimental | This single-arm study includes participants undergoing a non-invasive electrodiagnostic assessment to evaluate bioelectrical response patterns associated with viral antigen persistence. No therapeutic intervention is administered. Receives: Diagnostic Test: Electrodiagnostic Bioelectrical Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Bioelectrical Response Patterns Consistent With Viral Persistence
Non-invasive diagnostic assessment using electroacupuncture-based medicament testing to identify bioelectrical response patterns consistent with viral antigen persistence in participants with post-viral conditions.
Measured: At enrollment (single diagnostic session)
Secondary outcomes (1)
Distribution of Bioelectrical Reactivity Patterns During Medicament Testing
Measured: Baseline(Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start5 Dec 2025
- Primary completion30 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All enrolled participants undergo a single-session diagnostic assessment using medicament testing to evaluate bioelectrical response patterns associated with viral persistence.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oncology Center,Ministry Of Heath,Uzbekistan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Naylya Djumaeva, MD,PhD, Principal investigator, Reseacrh Institute of Virology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07343856
- Sponsor's protocol ID
- 9/36-2216
- Acronym
- EAV-LONGCOVID
- Status last verified
- Dec 2025
- First submitted
- 24 Dec 2025
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Personalized Alternative Non-invasive Rapid Diagnostic Test for SARS-CoV-2 in Patients With Long COVID
- ClinicalTrials.gov ID
- NCT07343856
- Acronym / sponsor ID
- EAV-LONGCOVID / 9/36-2216
- Keywords
- Long COVID, Post-acute sequelae of SARS-CoV-2 infection, Bioelectrical assessment, Electroacupuncture diagnostics, Medicament testing, Autonomic dysregulation, Chronic viral persistence, Non-invasive diagnostics
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Oncology Center,Ministry Of Heath,UzbekistanUniversity, hospital or other
- Study start
- 5 Dec 2025 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 15 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without administration of pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
Detailed description
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All enrolled participants undergo a single-session diagnostic assessment using medicament testing to evaluate bioelectrical response patterns associated with viral persistence.
| Arm | Type | Receives |
|---|---|---|
| Diagnostic Assesment Arm | Experimental | Diagnostic Test: Electrodiagnostic Bioelectrical AssessmentThis single-arm study includes participants undergoing a non-invasive electrodiagnostic assessment to evaluate bioelectrical response patterns associated with viral antigen persistence. No therapeutic intervention is administered. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18 years or older
- History of confirmed SARS-CoV-2 infection
- Persistent symptoms consistent with Long COVID lasting ≥12 weeks after acute infection
- Ability to provide informed consent
- Willingness to undergo non-invasive bioelectrical diagnostic assessment
Key exclusion criteria (5 listed)
- Acute infectious disease at the time of enrollment
- Severe uncontrolled medical or psychiatric conditions that may interfere with diagnostic assessment
- Implanted electronic medical devices (e.g., pacemaker)
- Pregnancy or breastfeeding
- Inability to comply with study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electrodiagnostic Bioelectrical AssessmentA non-invasive diagnostic procedure performed during a single session to assess bioelectrical response patterns associated with viral antigen persistence. Measurements are obtained using standardized bioelectrical assessment techniques without administration of any therapeutic agents or interventions. | Diagnostic test | Diagnostic Assesment Arm |
Primary outcome
Number of Participants With Bioelectrical Response Patterns Consistent With Viral Persistence
Time frame: At enrollment (single diagnostic session)
Non-invasive diagnostic assessment using electroacupuncture-based medicament testing to identify bioelectrical response patterns consistent with viral antigen persistence in participants with post-viral conditions.
1 secondary outcome
Distribution of Bioelectrical Reactivity Patterns During Medicament Testing
Time frame: Baseline(Day 1)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
RecruitingPhase 2
DAOIB for the Treatment of Brain Fog
Long COVID
Active, not recruitingObservational study
Pain in Long COVID-19: The Role of Sleep
Long COVID
Recruiting
Effect of Hi-OxSR for the Treatment of Post COVID Condition
Long COVID, Post COVID-19 Condition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Naylya Djumaeva, MD,PhD principal investigator
Reseacrh Institute of Virology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Electrodiagnostic Bioelectrical Assessment in people with Long COVID and Post-Acute Sequelae of SARS-CoV-2 Infection, run by Oncology Center,Ministry Of Heath,Uzbekistan at 1 site in Uzbekistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uzbekistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Bioelectrical Response Patterns Consistent With Viral Persistence (time frame: At enrollment (single diagnostic session)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.